352 related articles for article (PubMed ID: 24001178)
1. Hematopoietic stem cell mobilization for gene therapy: superior mobilization by the combination of granulocyte-colony stimulating factor plus plerixafor in patients with β-thalassemia major.
Yannaki E; Karponi G; Zervou F; Constantinou V; Bouinta A; Tachynopoulou V; Kotta K; Jonlin E; Papayannopoulou T; Anagnostopoulos A; Stamatoyannopoulos G
Hum Gene Ther; 2013 Oct; 24(10):852-60. PubMed ID: 24001178
[TBL] [Abstract][Full Text] [Related]
2. Plerixafor plus granulocyte colony-stimulating factor versus placebo plus granulocyte colony-stimulating factor for mobilization of CD34(+) hematopoietic stem cells in patients with multiple myeloma and low peripheral blood CD34(+) cell count: results of a subset analysis of a randomized trial.
Nademanee AP; DiPersio JF; Maziarz RT; Stadtmauer EA; Micallef IN; Stiff PJ; Hsu FJ; Bridger G; Bolwell BJ
Biol Blood Marrow Transplant; 2012 Oct; 18(10):1564-72. PubMed ID: 22683613
[TBL] [Abstract][Full Text] [Related]
3. The CXCR4 and adhesion molecule expression of CD34+ hematopoietic cells mobilized by "on-demand" addition of plerixafor to granulocyte-colony-stimulating factor.
Girbl T; Lunzer V; Greil R; Namberger K; Hartmann TN
Transfusion; 2014 Sep; 54(9):2325-35. PubMed ID: 24673458
[TBL] [Abstract][Full Text] [Related]
4. Superior long-term repopulating capacity of G-CSF+plerixafor-mobilized blood: implications for stem cell gene therapy by studies in the Hbb(th-3) mouse model.
Psatha N; Sgouramali E; Gkountis A; Siametis A; Baliakas P; Constantinou V; Athanasiou E; Arsenakis M; Anagnostopoulos A; Papayannopoulou T; Stamatoyannopoulos G; Yannaki E
Hum Gene Ther Methods; 2014 Dec; 25(6):317-27. PubMed ID: 25333506
[TBL] [Abstract][Full Text] [Related]
5. Plerixafor+G-CSF-mobilized CD34+ cells represent an optimal graft source for thalassemia gene therapy.
Karponi G; Psatha N; Lederer CW; Adair JE; Zervou F; Zogas N; Kleanthous M; Tsatalas C; Anagnostopoulos A; Sadelain M; Rivière I; Stamatoyannopoulos G; Yannaki E
Blood; 2015 Jul; 126(5):616-9. PubMed ID: 26089395
[TBL] [Abstract][Full Text] [Related]
6. Hematopoietic stem cell mobilization for gene therapy of adult patients with severe β-thalassemia: results of clinical trials using G-CSF or plerixafor in splenectomized and nonsplenectomized subjects.
Yannaki E; Papayannopoulou T; Jonlin E; Zervou F; Karponi G; Xagorari A; Becker P; Psatha N; Batsis I; Kaloyannidis P; Tahynopoulou V; Constantinou V; Bouinta A; Kotta K; Athanassiadou A; Anagnostopoulos A; Fassas A; Stamatoyannopoulos G
Mol Ther; 2012 Jan; 20(1):230-8. PubMed ID: 21952171
[TBL] [Abstract][Full Text] [Related]
7. Accelerated lymphocyte reconstitution and long-term recovery after transplantation of lentiviral-transduced rhesus CD34+ cells mobilized by G-CSF and plerixafor.
Uchida N; Bonifacino A; Krouse AE; Metzger ME; Csako G; Lee-Stroka A; Fasano RM; Leitman SF; Mattapallil JJ; Hsieh MM; Tisdale JF; Donahue RE
Exp Hematol; 2011 Jul; 39(7):795-805. PubMed ID: 21549175
[TBL] [Abstract][Full Text] [Related]
8. Impact of mobilization and remobilization strategies on achieving sufficient stem cell yields for autologous transplantation.
Pusic I; Jiang SY; Landua S; Uy GL; Rettig MP; Cashen AF; Westervelt P; Vij R; Abboud CN; Stockerl-Goldstein KE; Sempek DS; Smith AL; DiPersio JF
Biol Blood Marrow Transplant; 2008 Sep; 14(9):1045-1056. PubMed ID: 18721768
[TBL] [Abstract][Full Text] [Related]
9. Plerixafor and granulocyte-colony-stimulating factor (G-CSF) in patients with lymphoma and multiple myeloma previously failing mobilization with G-CSF with or without chemotherapy for autologous hematopoietic stem cell mobilization: the Austrian experience on a named patient program.
Worel N; Rosskopf K; Neumeister P; Kasparu H; Nachbaur D; Russ G; Namberger K; Witt V; Schloegl E; Zojer N; Linkesch W; Kalhs P; Greinix HT
Transfusion; 2011 May; 51(5):968-75. PubMed ID: 20880037
[TBL] [Abstract][Full Text] [Related]
10. Plerixafor (AMD3100) and granulocyte colony-stimulating factor (G-CSF) mobilize different CD34+ cell populations based on global gene and microRNA expression signatures.
Donahue RE; Jin P; Bonifacino AC; Metzger ME; Ren J; Wang E; Stroncek DF
Blood; 2009 Sep; 114(12):2530-41. PubMed ID: 19602709
[TBL] [Abstract][Full Text] [Related]
11. Successful stem cell remobilization using plerixafor (mozobil) plus granulocyte colony-stimulating factor in patients with non-hodgkin lymphoma: results from the plerixafor NHL phase 3 study rescue protocol.
Micallef IN; Stiff PJ; DiPersio JF; Maziarz RT; McCarty JM; Bridger G; Calandra G
Biol Blood Marrow Transplant; 2009 Dec; 15(12):1578-86. PubMed ID: 19896082
[TBL] [Abstract][Full Text] [Related]
12. Plerixafor: A chemokine receptor-4 antagonist for mobilization of hematopoietic stem cells for transplantation after high-dose chemotherapy for non-Hodgkin's lymphoma or multiple myeloma.
Steinberg M; Silva M
Clin Ther; 2010 May; 32(5):821-43. PubMed ID: 20685493
[TBL] [Abstract][Full Text] [Related]
13. Cost and clinical analysis of autologous hematopoietic stem cell mobilization with G-CSF and plerixafor compared to G-CSF and cyclophosphamide.
Shaughnessy P; Islas-Ohlmayer M; Murphy J; Hougham M; MacPherson J; Winkler K; Silva M; Steinberg M; Matous J; Selvey S; Maris M; McSweeney PA
Biol Blood Marrow Transplant; 2011 May; 17(5):729-36. PubMed ID: 20813198
[TBL] [Abstract][Full Text] [Related]
14. Plerixafor plus granulocyte colony-stimulating factor improves the mobilization of hematopoietic stem cells in patients with non-Hodgkin lymphoma and low circulating peripheral blood CD34+ cells.
Maziarz RT; Nademanee AP; Micallef IN; Stiff PJ; Calandra G; Angell J; Dipersio JF; Bolwell BJ
Biol Blood Marrow Transplant; 2013 Apr; 19(4):670-5. PubMed ID: 23333777
[TBL] [Abstract][Full Text] [Related]
15. CD34+ cell subclasses and lymphocyte subsets in blood grafts collected after various mobilization methods in myeloma patients.
Varmavuo V; Mäntymaa P; Silvennoinen R; Nousiainen T; Kuittinen T; Jantunen E
Transfusion; 2013 May; 53(5):1024-32. PubMed ID: 22897584
[TBL] [Abstract][Full Text] [Related]
16. Hematopoietic progenitor cell mobilization with "just-in-time" plerixafor approach is a cost-effective alternative to routine plerixafor use.
Veltri L; Cumpston A; Shillingburg A; Wen S; Luo J; Leadmon S; Watkins K; Craig M; Hamadani M; Kanate AS
Cytotherapy; 2015 Dec; 17(12):1785-92. PubMed ID: 26475754
[TBL] [Abstract][Full Text] [Related]
17. Autologous Stem Cell Mobilization in the Age of Plerixafor.
Cooper DL; Medoff E; Patel N; Baker J; Pratt K; Foss F; Seropian SE; Perreault S; Wu Y
Clin Lymphoma Myeloma Leuk; 2016 Jul; 16(7):411-6. PubMed ID: 27245311
[TBL] [Abstract][Full Text] [Related]
18. Plerixafor and granulocyte colony-stimulating factor for first-line steady-state autologous peripheral blood stem cell mobilization in lymphoma and multiple myeloma: results of the prospective PREDICT trial.
Russell N; Douglas K; Ho AD; Mohty M; Carlson K; Ossenkoppele GJ; Milone G; Pareja MO; Shaheen D; Willemsen A; Whitaker N; Chabannon C
Haematologica; 2013 Feb; 98(2):172-8. PubMed ID: 22983579
[TBL] [Abstract][Full Text] [Related]
19. Randomized cross-over trial of progenitor-cell mobilization: high-dose cyclophosphamide plus granulocyte colony-stimulating factor (G-CSF) versus granulocyte-macrophage colony-stimulating factor plus G-CSF.
Koç ON; Gerson SL; Cooper BW; Laughlin M; Meyerson H; Kutteh L; Fox RM; Szekely EM; Tainer N; Lazarus HM
J Clin Oncol; 2000 May; 18(9):1824-30. PubMed ID: 10784622
[TBL] [Abstract][Full Text] [Related]
20. Plerixafor injection: a hematopoietic stem cell mobilizer in non-Hodgkin lymphoma and multiple myeloma.
Jantunen E; Varmavuo V; Valtola J
Expert Rev Hematol; 2016 Aug; 9(8):723-32. PubMed ID: 27355397
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]